🕒 Wednesday 27 August 2025 Wed, 27 Aug 2025

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

GenusPlus Group has delivered a standout FY2025 with record revenue and profits, underpinned by strategic acquisitions and a booming renewable energy pipeline.

GenusPlus Group Ltd has reported a robust 36% increase in revenue and an 84% surge in net profit for FY2025, driven by strategic acquisitions and growth in the renewable energy sector. The company also declared a higher fully franked dividend, reflecting confidence in its expanding infrastructure footprint.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.

BPH Energy Limited reported a 49% increase in net profit for FY2025, driven by gains in its energy and biotech investments, while facing a pivotal Federal Court hearing over the renewal of the PEP-11 offshore gas exploration permit.

JB Hi-Fi Limited has updated its dividend notification to reflect the current exchange rate for New Zealand dollar payments, confirming a total dividend of AUD 2.05 per share fully franked.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Infragreen Group Ltd has reported a strong FY25 performance, exceeding its prospectus forecasts post-IPO and advancing its footprint in clean energy and waste recovery sectors. The company’s strategic acquisitions and organic growth set the stage for continued momentum into FY26.

Infragreen Group Limited has reported a robust FY25 performance, with pro forma revenue and EBITDA significantly exceeding forecasts, supported by a successful $40 million IPO.

Infragreen Group Limited reported a robust 190% increase in revenue for FY25 following its successful IPO, despite a significant statutory net loss. The company’s strategic acquisitions and expanded ownership stakes underpin a promising outlook in sustainable infrastructure.

SIV Capital Limited reported a statutory loss of $112,789 for the year ended June 2025, continuing its operational scale-down with only four active rental contracts. The company remains debt-free with $8.18 million in cash but its ASX securities remain suspended as it evaluates a confidential corporate opportunity.

Mayfield Group Holdings has raised its fully franked final dividend to 2.2 cents per share for FY25, reflecting solid financial health and promising ongoing shareholder returns.

Mayfield Group Holdings Ltd has reported a landmark financial year with revenues soaring nearly 38% and profits climbing over 32%, driven by strong demand in Data Centres and AI infrastructure sectors.

Zimplats Holdings Limited reported a strong financial rebound in FY2025, with revenue up 8% and net profit surging 393%, even as mined volumes dipped and no dividend was declared.

James Hardie Industries confirms its Q1 FY26 earnings met market expectations despite a challenging North American housing market, while revising its FY26 guidance following the AZEK acquisition.

OM Holdings has terminated a previous sale agreement for its 90% stake in OM Materials (Qinzhou) due to buyer issues and entered a new deal to sell 60% to Shaanxi Sinian Metal & Mining, aiming to bolster working capital.

US Masters Residential Property Group reported a modest portfolio valuation decline amid New York market uncertainty but maintained strong sales momentum and improved net operating income in Q2 2025.